Voyager Therapeutics is shifting towards a new technology to deliver gene therapy and away from a planned HD clinical trial. But this could lead to less invasive drugs in the long run, and many other companies are working on HD gene therapies.
HDBuzz reports from the annual Huntington’s disease therapeutics conference in Palm Springs
HDBuzz reports from the annual Huntington’s disease therapeutics conference in Palm Springs
Scientists screen the ENTIRE genome to find new potential therapeutic targets for HD. This ambitious study provides a wealth of data for HD researchers
Multiple teams find small differences in the 'CAG repeat' bit of the Huntington's disease gene. They don't directly change the huntingtin protein, but do alter the age of symptom onset. What's behind this enigma and what does it mean for patients?
New insights into the huntingtin protein, and further progress in turning genetic quirks that modify the course of HD into treatments, on the final day of the therapeutics conference
Finally, a big study that shows what childhood HD looks like. This will help us work out if new drugs work in children too
HDBuzz summarises all the science from the 2017 Huntington's Disease Therapeutics Conference in Malta - day 1
New technology enables researchers to find ultra-rare mutations in the HD gene, distinct from the one causing HD